NDA 211988 · Heron Theraps INC
Zynrelef Kit
Bupivacaine, Meloxicam · Periarticular · Nonsteroidal Anti-inflammatory Drug; Amide Local Anesthetic
Breakthrough therapyPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 17, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2021
May 12, 2021
Approved uses
3
Original approval plus efficacy supplements
Registered trials
2,839
342 Phase 3, 228 recruiting
FAERS reports
213
53 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1 ) ZYNRELEF is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or...
What it is approved for
From the label in effect Apr 20, 2026.
ZYNRELEF is indicated in adults for postsurgical analgesia for up to 72 hours after: soft tissue surgical procedures orthopedic surgical procedures – foot and ankle procedures – other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided [see Warnings and Precautions (5.10) ] ZYNRELEF is indicated in adults for postsurgical analgesia for up to 72 hours after: soft tissue surgical procedures orthopedic surgical procedures – foot and ankle procedures – other orthopedic surgical procedures (e.g., total joint arthroplasty) in which direct exposure to articular cartilage is avoided [see Warnings and Precautions (5.10) ] Limitations of Use Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures ( 1 ). Limitations of Use Safety and efficacy have not been established in highly vascular surgeries, such as intrathoracic, large 4 or more level spinal, and head and neck procedures.
Mechanism: ZYNRELEF is a fixed-dose combination of bupivacaine and meloxicam. Bupivacaine Local anesthetics block the generation and the conduction of nerve impulses presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 23, 2024 Supplement 13 · Efficacy LetterLabelReview
- Dec 8, 2021 Supplement 5 · Efficacy LetterLabelReview
- May 12, 2021 Original approval · Type 4 - New Combination · priority review Breakthrough therapyLetterLabelReview
4 products under this application
- ZYNRELEF KIT · BUPIVACAINE 200MG/7ML (29.25MG/ML); MELOXICAM 6MG/7ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Prescription
- ZYNRELEF KIT · BUPIVACAINE 300MG/10.5ML (29.25MG/ML); MELOXICAM 9MG/10.5ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Discontinued
- ZYNRELEF KIT · BUPIVACAINE 60MG/2.3ML (29.25MG/ML); MELOXICAM 1.8MG/2.3ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Discontinued
- ZYNRELEF KIT · BUPIVACAINE 400MG/14ML (29.25MG/ML); MELOXICAM 12MG/14ML (0.88MG/ML) · SOLUTION, EXTENDED RELEASE, PERIARTICULAR · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bupivacaine" as an intervention, any sponsor and status, largest first.
Vanderbilt University Medical CenterAcademic, hospital or other
NCT02726620 · 22,435 participants · Start Jan 5, 2017 · Primary completion Dec 31, 2017
Drug: Propofol; Sevoflurane and 32 more · For: Hypotension
Sites: Nashville, Tennessee
- Perioperative Multimodal Analgesia for Supratentorial CraniotomyPivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07441421 · 2,000 participants (planned) · Start Mar 9, 2026 · Primary completion Dec 31, 2027
Drug: Dexmedetomidine · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
Sites: Beijing, China
- Perioperative Multimodal Analgesia Protocol for Supratentorial CraniotomyPivotal-lookingNot yet recruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06406829 · 2,000 participants (planned) · Start Feb 9, 2026 · Primary completion Dec 31, 2026
Drug: Dexmedetomidine; Normal saline · For: Postoperative Pain; Analgesia; Supratentorial Brain Tumor
- A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis PainPivotal-lookingCompleted
Johns Hopkins UniversityAcademic, hospital or other
NCT04504812 · 1,937 participants · Start Feb 1, 2021 · Primary completion Apr 8, 2025
Drug: Duloxetine · For: Knee Osteoarthritis
Sites: Sacramento, California; San Diego, California; Aurora, Colorado · 24 sites in all
- Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)Pivotal-lookingRecruiting
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06452147 · 1,860 participants (planned) · Start Jun 19, 2024 · Primary completion Jul 30, 2028
Drug: Bupivacaine liposome; Regular local anesthetic and 1 more · For: Anesthesia; Hip Fractures; Dementia and 2 more
Sites: Dongyang, China; Hangzhou, China; Jinhua, China · 13 sites in all
- Catheter Outcomes With Sternotomy Cardiac OperatedPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01648777 · 1,502 participants · Start Mar 2012 · Primary completion Jan 2015
Drug: placebo · For: Pneumonia; Cardiac Surgery; Multiperforated Catheter and 2 more
Sites: Paris, France
- Efficacy and Safety of Intrathecal Morphine for Postoperative Pain Management Following Planned Caesarean SectionPivotal-lookingRecruiting
Anne Juul WikkelsøAcademic, hospital or other
NCT06797973 · 1,312 participants (planned) · Start Jul 15, 2025 · Primary completion May 31, 2027
Drug: Intrathecal Morphine; Placebo (Sodium Chloride Injection, 0.9%) · For: Caesarean Section; Postoperative Pain
Sites: Aarhus, Denmark; Copenhagen, Denmark; Herlev, Denmark · 9 sites in all
- Combined Spinal-epidural Anesthesia for Cesarean Section Without Prophylactical Prehydration and VasopressorsPivotal-lookingStatus unknown
Shenzhen People's HospitalAcademic, hospital or other
NCT03497364 · 930 participants (planned) · Start May 1, 2018 · Primary completion Nov 30, 2021
Drug: bupivacaine; ropivacaine · For: Cesarean Section; Anesthesia, Spinal
Sites: Shenzhen, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- wound dehiscence30
- suture related complication18
- procedural nausea17
- seroma12
- wound necrosis12
- skin odour abnormal11
- blister10
- pain10
- product odour abnormal10
- nausea9
- no adverse event9
- drug ineffective8
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 91 |
| 2023 | 58 |
| 2024 | 19 |
| 2025 | 24 |
| 2026 | 20 |
Recalls
1 FDA enforcement reports for this application.
Aug 2, 2022 · Class III · Terminated
Defective Delivery System: An incorrect 10 mL (12 mL) Luer (slip) syringe packaged in one lot of Zynrelef 400 mg/12 mg kit
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Analgesic Effectiveness of Liposomal Bupivacaine versus Plain Local Anesthetics for Abdominal Fascial Plane Blocks: A Systematic Review and Meta-analysis of Randomized Trials.
Hussain N, Speer J, Abdallah FW · Anesthesiology 2024 · Meta-Analysis, Systematic Review
- Liposomal Bupivacaine, Plain Bupivacaine, and Saline for Transversus Abdominis Plane Blocks: The CLEVELAND Randomized Trial.
Turan A, Ali Sakr Esa W, Brooker J, et al. · Anesthesiology 2026 · Randomized Controlled Trial
- Combined pectoralis and serratus anterior plane blocks with or without liposomal bupivacaine for minimally invasive thoracic surgery: A randomized clinical trial.
Marciniak D, Raymond D, Alfirevic A, et al. · J Clin Anesth 2024 · Randomized Controlled Trial
- Mepivacaine Versus Bupivacaine for Spinal Anesthesia: A Systematic Review and Meta-analysis of Random Controlled Trials.
Tan H, Wan T, Guo W, et al. · Adv Ther 2022 · Meta-Analysis, Systematic Review
- Liposomal bupivacaine versus conventional anesthetic or placebo for hemorrhoidectomy: a systematic review and meta-analysis.
Solis-Pazmino P, Figueroa L, La K, et al. · Tech Coloproctol 2024 · Meta-Analysis, Systematic Review
- Recovery quality of transversus abdominis plane block with liposomal bupivacaine after cesarean delivery: A randomized trial.
Liu HH, Qiu D, Xu DR, et al. · J Clin Anesth 2024 · Randomized Controlled Trial
Sponsor: Heron Theraps INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.